How fast a clinical-stage biotech spends cash — and exactly how many months are left before the next raise becomes existential.
Before a single dollar of burn or a single month of runway can be discussed, a clinical-stage biotech must establish one unambiguous fact: exactly how much cash and short-term investments it has on hand right now. This starting balance is the anchor for every subsequent calculation — runway, financing timing, and the credibility of management's own operating plan all derive from it.
The cash position reported in a biotech's financial statements is rarely just a checking-account balance. It typically aggregates several distinct line items into one figure that investors and boards treat as a single number:
• Cash and cash equivalents — bank deposits, money market funds, instruments with maturities under 90 days • Short-term investments — marketable securities (Treasuries, high-grade commercial paper) with maturities usually under 12 months, held for liquidity rather than yield • Sometimes excluded — restricted cash (e.g., collateral for a facility lease or a letter of credit), which is legally cash but not available to fund operations • Sometimes excluded — undrawn capacity on a debt facility or credit line, which is real but contingent liquidity, not cash in hand
Analysts and boards care about this distinction because two companies can report the same headline "cash" number while having meaningfully different amounts of truly deployable liquidity once restricted balances and covenant requirements are stripped out.
For a pre-revenue or early-revenue clinical-stage company, cash on hand is not just a balance sheet line — it is the clock. Every strategic decision (which trials to run, how many people to hire, whether to build in-house manufacturing or outsource it) is implicitly a decision about how fast that clock ticks down.
Public biotech investors scrutinize the quarterly cash balance disclosure specifically because it is one of the few forward-looking numbers management cannot easily spin: a lower-than-expected cash balance, even with an otherwise positive quarter of clinical progress, frequently moves the stock, because it directly shortens the implied runway and pulls the next dilutive financing event closer in time.
This is also why sophisticated management teams manage the optics of the cash position deliberately — timing non-dilutive deals, milestone payments, or a modest raise to land before a quarter-end close, so the reported starting balance for the next period looks as strong as possible.
A cash position is a snapshot, not a forecast — it says nothing on its own about how long that money will last. That is exactly why it must always be read together with the burn rate, never in isolation.
Burn rate is simply net cash outflow per month — but "net" is doing a lot of work in that sentence. Understanding burn requires decomposing it into its major cost buckets, distinguishing gross burn from net burn, and recognizing that these categories carry very different degrees of flexibility when cash gets tight.
Gross burn is the total cash a company spends in a month, full stop. Net burn subtracts any cash coming in the door — most commonly non-dilutive revenue from partnerships, licensing milestones, grants, or government contracts — from that gross figure.
Gross burn = Clinical trial costs + Personnel/G&A + Manufacturing/CMC + Facilities & other Net burn = Gross burn − Offsetting revenue (partnership payments, licensing income, grants)
The distinction matters enormously for runway math: two companies with identical gross spending can have very different real runways if one has a partner funding half its trial costs. Investors increasingly ask specifically for net burn guidance, because it is the number that actually determines how long the company's own cash will last — gross burn without context can make an otherwise well-funded, partnered program look far more precarious than it is.
For most clinical-stage biotechs, especially those running pivotal or late-stage trials, clinical costs are the single largest and most variable line item:
• CRO (contract research organization) fees — the largest sub-component for outsourced trials, often billed on a milestone or per-patient basis • Site payments — per-patient, per-visit fees to clinical trial sites, which scale directly with enrollment pace • Patient recruitment and retention — advertising, screening, travel reimbursement, increasingly important as trials compete for eligible patients • Investigational drug supply — manufacturing and distributing enough drug product to dose every trial arm, including placebo/comparator arms • Monitoring, data management, and regulatory costs — ongoing throughout the trial, not concentrated at start or finish
Clinical costs are also the most exposed to schedule risk: a slow-enrolling trial does not just delay a data readout, it extends the period during which the company must keep paying CRO and site fees, directly worsening burn efficiency even if the absolute monthly rate looks unchanged.
The remaining cost buckets behave very differently under stress, which matters when a company needs to cut burn quickly:
• Personnel & G&A is the most immediately actionable lever — headcount actions can measurably reduce burn within a single quarter, but they carry real costs in institutional knowledge, morale, and execution capacity, and severance itself is a one-time cash cost before savings materialize • Manufacturing/CMC spend is lumpy and batch-driven — a single scale-up run or validation batch can spike a quarter's spend well above trend, and this category is also the most prone to unplanned overruns from yield failures, tech-transfer delays, or facility issues • Facilities & other overhead is largely fixed in the short term — lease obligations, insurance, and core IT typically cannot be cut quickly without a lease renegotiation or subleasing effort, though they are usually the smallest share of total burn
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Clinical Trials & CRO | 45–60% | Patient recruitment, site fees, CRO management, investigational drug supply | Low — schedule-driven, hard to cut without delaying the trial itself |
| Personnel & G&A | 20–30% | Headcount, payroll & benefits, public-company reporting and compliance costs | Moderate — actionable via headcount decisions, but with real execution cost |
| Manufacturing / CMC | 10–20% | Drug substance/product batches, tech transfer, scale-up runs, stability studies | Low — batch-driven and lumpy, a common source of overruns |
| Facilities & Other | 5–10% | Lab/office lease, insurance, IT, general overhead | Low — largely fixed and slow to change short of a lease event |
Runway is deceptively simple arithmetic — current cash divided by net monthly burn — but it is the single most-watched, most-quoted, and most consequential metric in clinical-stage biotech finance. Every strategic conversation about hiring, trial design, and fundraising timing ultimately reduces to a debate about this one number.
Runway (months) = Cash on hand ÷ Net monthly burn
The result looks precise, but the burn figure feeding it is itself an estimate, and the method used to compute it materially changes the answer:
• Trailing average — burn calculated from the last 3–6 months of actual spend; simple and grounded in real data, but can understate future burn if spending is about to ramp (e.g., a pivotal trial about to enroll faster) • Forward-looking / budgeted burn — burn projected from the operating plan for the coming quarters; more accurate if the plan is realistic, but vulnerable to the same optimism bias that causes most biotech trials to run over budget and over schedule • Blended approach — many well-run finance teams use a forward-looking burn for guidance but stress-test it against the trailing actual trend as a sanity check
Companies disclosing "runway into 2028" versus "18 months of runway" are making a choice about how much precision and how much optimism to signal to the market — both are defensible, but they are not the same statement.
Runway concentrates an enormous amount of information into one figure that non-specialist investors, board members, and even employees can immediately understand, which is exactly why it dominates biotech financial communication:
• It directly predicts the timing of the next dilutive event — a near-term catalyst every current shareholder cares about • It is comparable across companies regardless of size — a $500M-cap company and a $50M-cap company can both be described in months of runway • It compresses clinical timeline risk and financial risk into a single number — a trial delay and a burn increase both show up as the same thing: shorter runway • It is one of the few forward metrics that is arithmetically simple enough that management cannot easily obscure it with adjusted or non-GAAP framing
The flip side is that runway's simplicity can also be misleading: it says nothing about whether the company will actually reach a value-creating milestone (like pivotal data) within that window, which is arguably the more important question runway is a proxy for.
Runway answers "how long until we run out of cash" — it does not answer "will we have accomplished anything worth financing by then." The two questions are frequently conflated, but only the second one determines whether the next raise will go well.
A single-point runway estimate is only as good as the assumptions behind it. Disciplined finance teams stress-test the baseline against realistic adverse scenarios — a trial delay, a cost-cut response, or a manufacturing overrun — to understand not just the expected runway, but the range of outcomes the company needs to be prepared for.
Clinical trials run over their planned timeline far more often than they run on or ahead of schedule — slow enrollment, protocol amendments, site activation delays, and safety-monitoring pauses are all common and individually unremarkable, but they compound. A trial that takes 30% longer than planned does not just delay the data readout by 30%: it extends the period during which the company must keep funding CRO fees, site payments, and drug supply at close to the original monthly rate, directly consuming additional cash that was not in the original runway estimate.
Sophisticated finance teams model this explicitly as a "burn duration" stress rather than only a "burn rate" stress — the monthly spend may not spike, but the number of months it must be sustained increases, which has the same effect on total cash consumed as a higher monthly rate would.
When a stress scenario shows runway falling below an uncomfortable threshold, the standard playbook is a cost-cut response, typically built from a combination of:
• Pipeline reprioritization — pausing or discontinuing earlier-stage or lower-conviction programs to concentrate cash on the lead asset most likely to reach a value-creating milestone • Headcount actions — reducing staff, most often in functions supporting deprioritized programs, which lowers personnel burn but carries real costs in severance, morale, and lost institutional knowledge • Vendor and CRO renegotiation — extending payment terms or rescoping contracts, often used as a bridge tactic rather than a structural fix • Facilities consolidation — subleasing or exiting excess lab/office space, though this typically takes longer to realize savings than personnel or pipeline actions
These levers genuinely extend runway, but each one also reduces the company's optionality and, in the case of pipeline cuts, its long-term value — which is exactly why boards treat a cost-cut decision as a last resort rather than a routine adjustment.
Unlike trial delays, which tend to erode runway gradually and visibly, manufacturing and CMC overruns can hit suddenly and are among the hardest cash risks to forecast: a failed batch, an unexpected yield shortfall, a tech-transfer delay to a new contract manufacturer, or a facility inspection finding can each consume months of budgeted spend in a single event.
Because manufacturing risk is lumpy rather than continuous, well-run finance teams typically hold a contingency buffer specifically against CMC risk rather than assuming the budgeted manufacturing line will play out smoothly — treating an overrun as a "when," not an "if," for any company running its own scale-up or technology transfer.
The single most important rule in biotech cash management is deceptively counterintuitive: the best time to start raising money is well before the company needs it, not when the balance sheet is running low. Best practice is to initiate the next financing with 12–18+ months of runway still remaining — because fundraising itself takes months, and negotiating leverage collapses as cash gets critically low.
A financing round is not an event that happens on the day cash runs out — it is a process that itself consumes months before a single dollar arrives: building the pitch and data package, engaging investment bankers or leading a direct process, meeting prospective investors, negotiating terms, and closing legal and diligence work routinely takes anywhere from three months for a fast, well-oversubscribed round to nine months or more for a more contested or structurally complex raise (a crossover round ahead of an IPO, a large strategic partnership-linked financing, or a raise during a difficult market window).
If a company waits until it has, say, six months of runway left before starting that process, it is racing a clock that the financing process itself cannot reliably beat — leaving no room for a slow market, a disappointing data readout, or investor due-diligence delays.
Runway level does not just determine whether a company can raise money — it determines the terms on which it can raise money, and this relationship is highly non-linear:
• At 12–18+ months of runway, a company can credibly walk away from an unattractive term sheet, run a competitive process among multiple investors, and negotiate price, board composition, and structural terms from relative strength • At 6–12 months, the company's leverage begins to erode — sophisticated investors know the calendar, and terms start reflecting the fact that the company has fewer viable alternatives to accepting a deal • Below 6 months, a company is frequently forced to accept whatever terms are available: a lower valuation (a "down round"), more dilutive structures (participating preferred, warrants, ratchets), tighter covenants, or reduced negotiating power over board control — all because the alternative to accepting the deal is running out of cash
This dynamic means the true cost of waiting too long to raise is rarely visible in the runway number itself — it shows up later, as excess dilution and lost control, in the terms of the round the company was ultimately forced to accept.
Boards and CFOs treat the runway falling below roughly 12–18 months as the trigger to actively begin the next financing process — not because cash is imminently running out, but because that is the point at which waiting any longer starts to cost real negotiating leverage.
When a company finds itself with less runway than it would like, a straight equity raise from a position of weakness is rarely the only option, and experienced management teams typically explore several avenues in parallel:
• Non-dilutive financing — grants, government or foundation funding, and royalty or venture-debt structures that extend runway without issuing new equity • Partnership or licensing deals — an upfront payment and ongoing cost-sharing from a pharma partner can both inject cash and reduce the company's own net burn going forward, doubly extending runway • Structured or bridge financing — convertible notes or a smaller bridge round designed to reach a specific near-term value-creating catalyst (such as a data readout) before attempting a larger, better-priced raise • Cost-cut response paired with a smaller raise — reducing burn (see Stage 4) to stretch existing cash further while a smaller, less dilutive financing covers the remaining gap
None of these fully substitutes for starting the core financing process early — but combined, they can meaningfully soften the terms a company is forced to accept when it has waited longer than it should have.